FEFriederike Egberts

Friederike Egberts

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Friederike Egberts has a total of 76 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Tropomyosin Receptor Kinase A Expression on Merkel Cell Carcinoma Cells

    by Ulrike Wehkamp, Sophie Stern, Sandra Krüger, Axel Hauschild, Christoph Röcken, Friederike Egberts

    Question Is tropomyosin receptor kinase A expressed in Merkel cell carcinoma? Findings In this case series study, tropomyosin receptor kinase A expression on tumor cells was detected in every evaluable case of Merkel cell carcinoma. Meaning Expression of tropomyosin receptor kinase A on tumor cells in Merkel cell carcinoma may be a rationale for targeted therapy. Importance Merkel cell carcinoma (MCC) is a malignant neuroendocrine skin tumor frequently associated with the Merkel cell polyomavirus. Immune checkpoint therapy showed remarkable results, although not all patients are responsive to this therapy. Anti–tropomyosin receptor kinase A (TrkA)–targeted treatment has shown promising results in several tumor entities. Objective To determine TrkA expression in MCC as a rationale for potential targeted therapy. Design, Setting, and Participants This case series study investigated the MCC specimens of 55 patients treated at the Department of Dermatology, University Hospital of Schleswig-Holstein, Kiel, Germany, from January 1, 2005, through December 31, 2015. Thirty-nine of the 55 samples were suitable for further histopathologic examination. Expression of TrkA was explored by immunohistochemical analysis. Exposure Diagnosis of MCC was confirmed by staining positive for cytokeratin 20 (CK20) and synaptophysin. Main Outcomes and Measures Expression of TrkA on the tumor cells. Results Specimens of 39 patients (21 women and 18 men; mean [SD] age, 75.0 [7.8] years) underwent immunohistochemical investigation. Thirty-eight of 38 specimens expressed CK20 and synaptophysin on the MCC tumor cells (100% expression). Merkel cell polyomavirus was detected in 32 of 38 specimens (84%). Tropomyosin receptor kinase A was found in all 36 evaluable specimens on the tumor cells; 34 (94%) showed a weak and 2 (6%) showed a strong cytoplasmic expression. In addition, strongly positive perinuclear dots were observed in 30 of 36 specimens (83%). Conclusions and Relevance Tropomyosin receptor kinase A was expressed on MCC tumor cells in 100% of evaluable specimens. This result may lead to the exploration of new targeted treatment options in MCC, especially for patients who do not respond to anti–programmed cell death protein 1 treatment.


  • Tumor vascularization and clinicopathologic parameters as prognostic factors in merkel cell carcinoma

    by A. Bob, F. Nielen, J. Krediet, J. Schmitter, D. Freundt, D. Terhorst, J. Röwert-Huber, J. Kanitakis, E. Stockfleth, Ch. Ulrich, et al.

    Purpose Merkel cell carcinoma (MCC) is a rare but aggressive neuroendocrine tumor of the skin with an increasing incidence. The clinical course is variable and reliable prognostic factors are scarce. Tumor angiogenesis has been shown to have prognostic impact in different types of cancer. The aim of our study was to determine potential prognostic factors, including tumor vascularization, for clinical outcome of MCC. Methods The medical records of 46 patients with MCC diagnosed between 1997 and 2010 were analyzed retrospectively. Tissue samples were immune-stained for the lymphatic endothelial vessel marker podoplanin/D2-40 and the panvascular marker CD31. These immunostained sections were analyzed using computer-assisted morphometric image analyses. Aside from the parameters of tumor vascularization, clinicopathologic features were investigated, and progression-free survival (PFS) and tumor-specific survival (TSS) were assessed. Univariate and multivariate analyses were performed to determine prognostic factors. Results Male sex of the MCC patients and a high cross-sectional whole vessel area (WVA) in relation to the entire tumor area as determined on CD31-stained tumor sections were found to be negative prognostic factors for PFS in a univariate and multivariate regression analysis. Ulceration of the primary tumor was significantly associated with both impaired PFS and TSS. Conclusions Our results indicate a high prognostic impact of tumor vascularization on the clinical outcome of MCC patients. Male sex and ulceration of the primary MCC were identified as independent unfavorable prognostic markers for the clinical outcome. As an outlook, MCC patients with increased angiogenesis might be identified and subjected to a targeted anti-angiogenic treatment.


  • Varying Mutational Alterations in Multiple Primary Melanomas

    by Friederike Egberts, Ann-Sophie Bohne, Sandra Krüger, Jürgen Hedderich, Rainer Rompel, Jochen Haag, Christoph Röcken, Axel Hauschild


  • Melanomas of unknown primary frequently harbor TERT-promoter mutations

    by Friederike Egberts, Sandra Krüger, Hans M. Behrens, Inka Bergner, Giorgios Papaspyrou, Jochen A. Werner, Ibrahim Alkatout, Jochen Haag, Axel Hauschild, Christoph Röcken

    Commonly, in patients with melanoma metastases of an unknown primary tumor (MUP), an extensive search for the primary tumor is carried out. Recently, highly recurrent telomerase reverse transcriptase (TERT)-promoter mutations were found in malignant melanomas, which may function as driver mutations of skin cancer. The aim of this study was to test the hypothesis that MUP and mucosal melanomas harbor different prevalences of TERT-promoter mutations. Thirty-nine patients with MUP and 53 patients with mucosal melanomas were retrieved. In total, 152 paraffin samples of 92 patients were analyzed, and in 38 patients, multiple samples were tested. Mutational analysis of the TERT-promoter, BRAF, NRAS, and KIT genes was carried out. In total, 92 patients were eligible for mutational analysis. TERT-promoter mutations were found in 33 patients (35.9%): chr5, 1,295,228 C>T (18 patients); chr5, 1,295,250 C>T (11 patients); chr5, 1,295,228–229 CC>TT (three patients); chr5, 1,295,242–243 CC>TT (one patient). The mutations were significantly more prevalent in MUP [26 (66.7%)] than in mucosal melanomas [seven patients (13.2%); PBRAF mutations were found in 46.2% of patients (18 patients) and NRAS mutations in 28.2% of patients (11 patients). In mucosal melanoma, NRAS mutations were found in 18.9% of patients (10), and BRAF and KIT mutations in 7.5% of patients (four patients), respectively. The prevalence of TERT-promoter mutations was associated with the patient's sex [23 (51.1%) men, 10 (21.3%) women; P=0.004]. No significant correlation was found between TERT-mutation and patient survival. The TERT-promoter genotype of MUP points toward a cutaneous and not mucosal origin. The significant sex differences merit further attention in having putative therapeutic implications.


  • Open Access

    Metastatic melanoma of unknown primary resembles the genotype of cutaneous melanomas

    by F. Egberts, I. Bergner, S. Krüger, J. Haag, H. M. Behrens, A. Hauschild, C. Röcken

    Although 90% of all melanomas are of cutaneous origin, some patients present with melanoma metastases of unknown origin (MUP). Commonly, in these patients an extensive search for the primary tumor is carried out. In the past, genetic analyses have shown substantial differences in pathogenetic mutations among cutaneous, acral and mucosal melanomas. The aim of this study was to assess the mutational status of MUP in order to better characterize the putative origin of the primary tumor and to evaluate potential prognostic factors. The medical records of 44 patients with MUP were analyzed and a survival analysis was conducted. In total, 66 paraffin samples of 44 patients were analyzed, and in 15 patients multiple metastases were tested. Mutational analysis of the BRAF, NRAS and KIT genes was carried out. Twenty-three patients (52.3%) had a mutation in the BRAF gene and 12 patients (23.8%) had a mutation in the NRAS gene. There were neither mutations in the KIT gene. In patients with multiple samples, there was 100% consistency regarding mutational status among the different metastases. The median overall survival (OS) was 86.4 months (39–134). The American Joint Committee on Cancer stage at first diagnosis of metastatic melanoma (stage III versus IV) was significantly associated with OS (P < 0.001), BRAF or NRAS mutation status had no significant prognostic impact on clinical outcomes. MUP resembles the genotype of cutaneous melanoma and not that of mucosal melanomas.


  • DNp73 Exerts Function in Metastasis Initiation by Disconnecting the Inhibitory Role of EPLIN on IGF1R-AKT/STAT3 Signaling

    by Marc Steder, Vijay Alla, Claudia Meier, Alf Spitschak, Jens Pahnke, Katharina Fürst, Bhavani S. Kowtharapu, David Engelmann, Janine Petigk, Friederike Egberts, et al.


  • Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma

    by Friederike Egberts, Eva Maria Kotthoff, Sascha Gerdes, Jan Hendrik Egberts, Michael Weichenthal, Axel Hauschild


  • Adjuvante systemische Therapie des Melanoms

    by K.C. Kähler, F. Egberts, A. Hauschild, P. Mohr

  • Sorafenib and pegylated interferon-alpha-2b in advanced metastatic melanoma: A multicenter phase II DeCOG trial.

    by A. Hauschild, R. Gutzmer, S. Ugurel, U. Trefzer, F. Egberts, J. Hassel, D. Schadendorf, C. Mauch, C. Garbe, M. Weichenthal

    8526 Background: There is no standard of care for advanced metastatic melanoma (MM). Therefore the combination of a multi-kinase inhibitor such as sorafenib, and pegylated interferon alfa-2b (PegIFN), as previously used in renal cell cancer with some success, could potentially lead to an improved anti-tumoral response. Methods: Patients (pts) with previously untreated (excluding immunotherapy in the adjuvant setting), stage IV MM without brain metastasis, ECOG performance status 0-1 were eligible. All pts received PegIFN 3 μ g/kg weekly once per week, and sorafenib 400 mg BID until progressive disease (PD). The primary endpoint was disease control rate (DCR) defined as CR+PR+SD after 8 weeks of treatment. Results: From February 2008 to February 2009, 55 pts were enrolled (ITT population). The median age was 64 years (range: 20-85); Pts were categorized as following: stage IV M1a/b/c = 3/9/43. 41 pts (75%) received at least 8 weeks of treatment. Prior to 8 weeks evaluation, 9 pts withdrew due to toxicity, 2 revoked consent, and 3 had overt PD. At 8 weeks, 3 pts (5.5%) had a PR, 14 (25.5%) had a SD, resulting in a 31% DCR. Median PFS in these pts was 2.1 months (95%CI: 1.9–2.3). The toxicity of this combination was mainly haematological. Serious brain and GI bleeding complications occurred in 4 pts, where 2 had a fatal outcome. Other grade ¾ toxicities were fatigue and flu- like symptoms. Conclusions: The combination of sorafenib and PegIFN showed modest clinical activity and some serious side effects including fatal bleeding complications. Due to these findings further testing of this combination is not warranted. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Bayer Health Care, Schering-Plough Bayer Health Care, Schering-Plough Bayer Health Care, Schering-Plough

  • Clinicopathologic prognostic markers of survival: an analysis of 259 patients with malignant melanoma ≥1 mm

    by Friederike Egberts, A. Momkvist, J. H. Egberts, K. C. Kaehler, M. Weichenthal, A. Hauschild

    The histopathologic status of the sentinel node (SN) and the ulceration of the primary tumor are important indicators of the clinical outcome of melanoma patients. The purpose of this study was to investigate potential correlations between prognostic factors and the sentinel lymph node status as well as their influence on disease-free survival (DFS), distant metastases-free survival (DMFS), and overall survival (OS). The medical records of 259 melanoma patients who underwent sentinel lymph node dissection between 2000 and 2006 were analyzed. DFS, DMFS, and OS were assessed. A uni- and a multivariate analysis to determine prognostic factors were performed. Histologic type, Clark’s level, and Breslow’s tumor thickness were the only parameters that showed a significant correlation with a positive SN. The univariate analysis revealed SN positivity (DFS and DMFS: p < 0.001; OS: p = 0.039) and ulceration (DFS: p < 0.001; DMFS: p = 0.001; OS: p = 0.003) to be significant prognostic markers. However, ulceration was the only independent prognostic factor for OS that was upheld by the multivariate analysis (p = 0.006; HR 3.89; CI 1.48–10.27). In stage I/II melanoma patients, ulceration of the primary tumor was the strongest prognostic factor for RFS, DMFS, and OS and superior to the pathology status of the SN.